Pharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today.
Owlstone’s ReCiva breath sampler, which has CE Mark clearance in the E.U., captures volatile organic compounds in a patient’s breath. A VOC profile can be used to non-invasively diagnose disease at a very early stage and monitor treatment response, according to Owlstone.
Get the full story at our sister site, Drug Delivery Business News.
The post AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers appeared first on MassDevice.
from MassDevice https://ift.tt/2qgoOru
Cap comentari:
Publica un comentari a l'entrada